Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center
Authors:
- Thierry DucruetTDThierry Ducruet
- Marie-Claude LevasseurMLMarie-Claude Levasseur
- Anne Des RochesARAnne Des Roches
- Ayman KafalAKAyman Kafal
- Renée DicaireRDRenée Dicaire
- Elie HaddadEHElie Haddad
- 1 February 2013
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 131 (2) , 585-587.e3
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapyClinical Immunology, 2011
- Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary ImmunodeficiencyJournal of Clinical Immunology, 2010
- Economic evaluation of immunoglobulin replacement in patients with primary antibody deficienciesClinical and Experimental Immunology, 2009
- Primary immunodeficiencies: 2009 updateJournal of Allergy and Clinical Immunology, 2009
- Economic Assessment of Different Modalities of Immunoglobulin Replacement TherapyImmunology and Allergy Clinics of North America, 2008
- Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency DiseasesJournal of Clinical Immunology, 2006
- Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National StudyJournal of Clinical Immunology, 2006
- Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insuranceThe European Journal of Health Economics, 2005
- Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJournal of Allergy and Clinical Immunology, 2004
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995